Last Update:
December 08, 2014
Documents identified with this icon are in Portable Document Format (PDF)
and require the
Adobe
Acrobat Reader
Analysis of clinical outcomes in African American HIV-1
positive patients receiving lopinavir/ritonavir
in a large urban AIDS clinic
P. Kadlecik, R. Hao
PDF Poster
Abstract
POSTER
Limited future regimen options for those starting on NNRTI-based triple
combinations due to
antiretroviral drug resistance mutations
K.J. Chan, R. Harrigan, D. Moore, et al
PDF Poster
Abstract
POSTER
Clinical outcomes, immmunologic function and virologic suppression among HIV
infected children
receiving Lopinavir/ritonavir-based second line antiretroviral therapy at
National Pediatric Hospital,
Phnom Penh, Cambodia
S. Sophan, E. Nerrienet, U. Vibol, et al
PDF Poster
Abstract
A WEEK-IN-REVIEW FEATURED REPORT
POSTER
Comparison of total and unbound lopinavir (LPV) pharmacokinetics (PK) in
HIV-infected pregnant
women receiving lopinavir/ritonavir (LPV/r) soft-gel capsules (SGC) or
tablets
G.P. Taylor, L. Else, L. Dickenson, et al|
PDF Poster
Abstract
POSTER
Single boosted protease inhibitor versus double boosted protease inhibitors
for the salvage therapy
in HIV-infected patients
W. Manosuthi, W. Amornnimit, S. Chimsutorn, et al
PDF Poster
Abstract
Antiretroviral
monotherapy with ritonavir-boosted lopinavir or fosamprenavir in
HIV-cirrhotic patients
is a safe,
effective and costs-saving strategy
A.
Moreno-Zamora, M.J. Pérez-Elías, J.L. Casado,
et al
Abstract
Lopinavir/ritonavir combined with raltegravir demonstrated similar antiviral
efficacy and safety as
lopinavir/ritonavir combined with tenofovir disoproxil
fumarate/emtricitabine in treatment-naïve HIV-1
infected subjects
J. Reynes, A. Lawal, F. Pulido, et al
Abstract
Baseline HIV-1
RNA does not affect virologic response to lopinavir/ritonavir-based regimens
in
antiretroviral-naive subjects: results of a 96-week meta-analysis of >2400
subjects
J. van Wyk, R. Qaqish, K. Hollar, et al
Abstract
Market shift
towards heat-stable lopinavir/ritonavir demonstrates the need for improved
formulations
for second line treatment of HIV/AIDS in low- and middle-income countries
B. Waning, E. Diedrichsen, S. Moon, et al
Abstract
The effect of
lopinavir/r monotherapy on viral load and on the selection of
resistance-associated
mutations in seminal plasma
E. Nunes, M. Santini-Oliveira, S. Tubo, et al
Abstract
Incidence of
emtricitabine, tenofovir, raltegravir, and lopinavir resistance following
twice-daily (BID)
lopinavir/ritonavir (LPV/r) in combination with once-daily (QD)
emtricitabine/tenofovir (FTC/TDF) or
twice daily
raltegravir (RAL) in antiretroviral-naïve, HIV-1 infected subjects: 48-week
results of a
96-week randomized
trial (study M10-336)
A. Lawal, L. Maroldo, R. Rivero, et al
Abstract
The effect of
lopinavir/ritonavir on the pharmacokinetics of TMC207, an investigational
antimycobacterial
agent
R. van Heeswijk, A. Vandevoorde, P. Meyvisch, et al
Abstract
Real-life safety
and efficacy of lopinavir/ritonavir (LPV/r) in drug-naive and antiretroviral
(ARV) treatment-
experienced HIV
patients: 96-week follow-up
B. Conway, J. DeWet, A. Tsang, et al
Abstract
|
XVIII International AIDS Conference |
| |
KLS
Main Page